3,5-diiodo-L-thyronine (3,5-T2)

Catalog No.S6474 Synonyms: NSC 90469

For research use only.

3,5-diiodo-L-thyronine (3,5-T2, NSC 90469) is an endogenous metabolite of thyroid hormones. 3,5-Diiodo-l-thyronine has been proposed as a potential hypolipidemic agent for treatment of obesity and hepatic steatosis.

3,5-diiodo-L-thyronine (3,5-T2) Chemical Structure

CAS No. 1041-01-6

Purity & Quality Control

Related Other Products

Biological Activity

Description 3,5-diiodo-L-thyronine (3,5-T2, NSC 90469) is an endogenous metabolite of thyroid hormones. 3,5-Diiodo-l-thyronine has been proposed as a potential hypolipidemic agent for treatment of obesity and hepatic steatosis.

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 525.08
Formula

C15H13I2NO4

CAS No. 1041-01-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC(=CC=C1O)OC2=C(C=C(C=C2I)CC(C(=O)O)N)I

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04795856 Recruiting Drug: [11C] acetate Mitral Valve Regurgitation University of Alabama at Birmingham June 18 2025 Early Phase 1
NCT04134910 Not yet recruiting Procedure: Physical Therapy Back Pain|Intervertebral Disc Degeneration VA Office of Research and Development May 2 2023 Not Applicable
NCT05333432 Not yet recruiting Procedure: Multiparameric MRI with injection Prostate Cancer Assistance Publique - Hôpitaux de Paris|National Cancer Institute France October 1 2022 Not Applicable
NCT05046782 Not yet recruiting Device: restriction spectrum imaging (RSI) Prostate Cancer M.D. Anderson Cancer Center September 30 2022 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy 3,5-diiodo-L-thyronine (3,5-T2) | 3,5-diiodo-L-thyronine (3,5-T2) supplier | purchase 3,5-diiodo-L-thyronine (3,5-T2) | 3,5-diiodo-L-thyronine (3,5-T2) cost | 3,5-diiodo-L-thyronine (3,5-T2) manufacturer | order 3,5-diiodo-L-thyronine (3,5-T2) | 3,5-diiodo-L-thyronine (3,5-T2) distributor